Newswire (Published: Tuesday, October 17, 2017, Received: Thursday, October 12, 2017, 10:53:41 AM CDT)

Word Count: 445

Data on Prostate Cancer Discussed by Researchers at Biotechnology Research Center (Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer)

By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology - Prostate Cancer have been published. According to news originating from Mashhad, Iran, by NewsRx correspondents, research stated, "Prostate cancer is the second most commonly diagnosed cancer among men worldwide. Identifying new prognostic and predictive biomarkers will help stratification of prostate cancer patients for a better treatment."

Our news journalists obtained a quote from the research from Biotechnology Research Center, "Gankyrin is a novel oncoprotein which regulates cell cycle and protein degradation. Gankyrin overexpression correlated with the malignant phenotypes and promotes the tumorigenicity and metastasis in many cancers. However, there are not any reports on the role of Gankyrin in prostate cancer. Therefore, this study was designed to investigate the expression of Gankyrin in prostate cancer and analyze its correlation with some clinicopathological characteristics. We characterized the expression of gankyrin in fifty five prostate cancer specimens and twenty non-cancerous tissues by immunohistochemical staining and the results were correlated with clinical characteristics and pathological parameters. Gankyrin was expressed in 41 of 55 (74%) prostate cancer patients and its expression was significantly higher than corresponding adjacent normal tissues (p <0.001). Gankyrin overexpression was significantly correlated with histopathological tumor grade, Gleason score and tumor differentiation (P=0.002)."

According to the news editors, the research concluded: "These findings showed that Gankyrin is mainly overexpressed in high grade prostate tumors so it may have a significant role in prostate cancer progress and it May serve as a useful biomarker for the identification of aggressive prostate cancers."

For more information on this research see: Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer. Neoplasma, 2017;64(5):732-737. Neoplasma can be contacted at: Aepress Sro, Bajzova 7, Bratislava, 821 08, Slovakia (see also Oncology - Prostate Cancer).

The news correspondents report that additional information may be obtained from K. Jamialahmadi, Mashhad Univ Med Sci, Biotechnol Res Center, Mashhad, Iran. Additional authors for this research include N.S. Sistani, P. Zamani, K. Abnous and M.M. Riahi.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.4149/neo_2017_511. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Mashhad, Iran, Asia, Cancer, Diagnostics and Screening, Prostatic Neoplasms, Prostate Cancer, Oncology, Biotechnology Research Center.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Eastern Europe
Southern Asia
Iran
Slovakia
Asia
Europe
Mashhad
Bratislava

Subjects

Science and Technology
      Scientific Research
      Technology
            Applied Biotechnology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research